Pulmonology at Ruijin Hospital Shanghai | CMCS

Expert Respiratory Care at One of China's Premier Academic Medical Centers

The Department of Pulmonology at Ruijin Hospital — affiliated with Shanghai Jiao Tong University School of Medicine — is one of China's most distinguished and research-active respiratory medicine centers, with a national reputation for excellence in the diagnosis and management of lung infections, interstitial lung disease, COPD, asthma, lung cancer, and critical respiratory illness. The department combines outstanding clinical expertise with a productive research program, offering international patients access to some of China's most eminent pulmonologists and the latest evidence-based treatments for complex respiratory conditions.

For international patients seeking expert pulmonology care in Shanghai — whether for a complex lung infection, difficult-to-diagnose interstitial lung disease, severe asthma, or a second opinion on a challenging respiratory diagnosis — Ruijin Hospital's pulmonology department represents one of the most compelling destinations in Asia. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international patients throughout their care journey.

About the Department

Ruijin Hospital's pulmonology department is a national key clinical specialty operating a comprehensive respiratory unit that includes dedicated inpatient respiratory wards, a respiratory intensive care unit (RICU), a pulmonary function laboratory, a bronchoscopy center, a sleep medicine service, an interstitial lung disease (ILD) clinic, a severe asthma clinic, and a lung infection service. The department is particularly recognized for its expertise in respiratory infections — including community-acquired pneumonia, hospital-acquired pneumonia, and emerging infectious respiratory diseases — and has been at the forefront of China's response to major respiratory infectious disease outbreaks.

Faculty members publish regularly in leading respiratory and infectious disease journals including American Journal of Respiratory and Critical Care Medicine, European Respiratory Journal, Chest, Lancet Respiratory Medicine, and Clinical Infectious Diseases.

Conditions Treated

• Community-Acquired Pneumonia (CAP) — Comprehensive management including severe CAP requiring ICU care; pathogen-directed antibiotic therapy; atypical pneumonia (Legionella, Mycoplasma, Chlamydia)
• Hospital-Acquired & Ventilator-Associated Pneumonia — MDR organism management; carbapenem-resistant organism (CRO) infections
• Pulmonary Tuberculosis — Drug-sensitive and drug-resistant TB; MDR-TB and XDR-TB management with novel regimens (bedaquiline, delamanid, pretomanid)
• Non-Tuberculous Mycobacteria (NTM) — MAC, M. abscessus, and other NTM lung disease; guideline-based antibiotic regimens
• Invasive Fungal Infections — Aspergillosis, cryptococcosis, and Pneumocystis pneumonia in immunocompromised patients
• Chronic Obstructive Pulmonary Disease (COPD) — Stable COPD management and exacerbation treatment; optimized inhaler therapy; pulmonary rehabilitation
• Asthma — Mild to severe and difficult-to-treat asthma; biologic therapy (dupilumab, mepolizumab, benralizumab, tezepelumab) for severe eosinophilic and type 2 asthma
• Idiopathic Pulmonary Fibrosis (IPF) — Antifibrotic therapy (nintedanib, pirfenidone); lung transplantation evaluation
• Interstitial Lung Disease (ILD) — Connective tissue disease-associated ILD, hypersensitivity pneumonitis, sarcoidosis, and rare ILDs; multidisciplinary ILD diagnosis and management
• Bronchiectasis — Airway clearance, infection management, and long-term antibiotic strategies
• Pulmonary Hypertension — Group 1 PAH targeted vasodilator therapy (ERA, PDE5i, prostacyclin analogues, riociguat); group 3 and 4 PH management
• Lung Cancer — Bronchoscopic diagnosis and staging; EBUS-guided lymph node sampling; coordination with thoracic surgery and oncology for multidisciplinary management
• Pleural Disease — Pleural effusion diagnosis and management; thoracentesis, chest drain insertion, and medical thoracoscopy
• Sleep-Disordered Breathing — Obstructive sleep apnea diagnosis (polysomnography) and CPAP/BiPAP therapy; obesity hypoventilation syndrome
• Respiratory Failure — Non-invasive ventilation (NIV), high-flow nasal oxygen (HFNO), and invasive mechanical ventilation in the RICU
• Post-COVID Pulmonary Complications — Post-COVID ILD, pulmonary fibrosis, and persistent respiratory symptoms

Leading Specialist

Prof. Qu Jieming (矍介明) — Director, Pulmonology

Prof. Qu Jieming is one of China's most eminent pulmonologists and a nationally and internationally recognized authority in respiratory infections, interstitial lung disease, and critical respiratory medicine. As Director of the Department of Pulmonology at Ruijin Hospital, he leads one of China's most productive respiratory medicine clinical and research programs.

Prof. Qu is particularly recognized for his expertise in the management of severe and complex respiratory infections, including community-acquired pneumonia, drug-resistant tuberculosis, non-tuberculous mycobacterial lung disease, and invasive fungal infections in immunocompromised patients. His clinical program has been at the forefront of China's response to emerging respiratory infectious diseases, and he has been a key contributor to national guidelines for pneumonia, COPD, and respiratory infection management.

In interstitial lung disease, Prof. Qu leads a multidisciplinary ILD program that provides expert diagnosis and management for patients with IPF, connective tissue disease-associated ILD, hypersensitivity pneumonitis, and rare ILDs — using the full range of diagnostic tools including HRCT, bronchoscopy with BAL and transbronchial biopsy, and surgical lung biopsy where required. His research on respiratory infections and ILD has been published in leading journals including American Journal of Respiratory and Critical Care Medicine, European Respiratory Journal, and Lancet Respiratory Medicine.

Bronchoscopy & Interventional Pulmonology

Ruijin's bronchoscopy center offers the full range of diagnostic and therapeutic bronchoscopic procedures:

Diagnostic Bronchoscopy

• Flexible Bronchoscopy with BAL — Bronchoalveolar lavage for infection diagnosis, ILD evaluation, and cytological assessment
• Endobronchial Ultrasound (EBUS) — EBUS-TBNA for mediastinal lymph node sampling and lung cancer staging
• Transbronchial Lung Biopsy (TBLB) — For ILD diagnosis and peripheral lung lesions
• Cryobiopsy — Transbronchial cryobiopsy for ILD diagnosis with larger, better-preserved specimens
• Navigational Bronchoscopy — Electromagnetic navigation for peripheral lung lesion biopsy
• Medical Thoracoscopy — Pleural biopsy and pleurodesis for pleural disease

Therapeutic Bronchoscopy

• Bronchial Thermoplasty — For severe refractory asthma not controlled by biologic therapy
• Endobronchial Valve Placement — Bronchoscopic lung volume reduction for severe emphysema
• Airway Stenting — For malignant and benign central airway obstruction
• Laser & Cryotherapy — For endobronchial tumor debulking

Severe Asthma Biologic Program

Ruijin's severe asthma program is one of the most comprehensive in Shanghai, offering the full range of approved biologic therapies for patients with severe, uncontrolled asthma:

• Dupilumab — Anti-IL-4Rα for type 2 asthma with eosinophilia and/or elevated FeNO
• Mepolizumab & Benralizumab — Anti-IL-5/IL-5R for severe eosinophilic asthma
• Tezepelumab — Anti-TSLP for severe asthma regardless of eosinophil count
• Omalizumab — Anti-IgE for severe allergic asthma

ILD Multidisciplinary Program

Ruijin's ILD program follows a rigorous multidisciplinary diagnostic approach, with all complex ILD cases reviewed by a dedicated MDT comprising pulmonologists, radiologists, and pathologists. The MDT uses the latest ATS/ERS/JRS/ALAT guidelines for ILD classification and management, ensuring that patients receive accurate diagnoses and evidence-based treatment plans.

Why International Patients Choose Ruijin Pulmonology

• Respiratory Infection Expertise — National leadership in complex pneumonia, drug-resistant TB, NTM, and fungal lung infections
• ILD Multidisciplinary Program — Expert diagnosis and management of IPF, CTD-ILD, and rare ILDs with full bronchoscopic and pathological capabilities
• Severe Asthma Biologic Program — Full range of approved biologics for severe uncontrolled asthma
• Advanced Bronchoscopy — EBUS, cryobiopsy, bronchial thermoplasty, and endobronchial valve placement
• Critical Care Capability — Dedicated RICU with NIV, HFNO, and invasive ventilation for severe respiratory failure
• Cost-Effectiveness — World-class respiratory care at significantly lower cost than equivalent treatment in Western countries

The CMCS Patient Journey

1. Initial Inquiry — Share your respiratory history, pulmonary function tests, CT scans, bronchoscopy reports, microbiological results, and current medications with CMCS.
2. Medical Record Preparation — We translate and organize your records for specialist pre-consultation review.
3. Specialist Matching — We identify the most appropriate pulmonologist based on your condition — infection, ILD, asthma, COPD, or pulmonary hypertension.
4. Priority Scheduling — We secure a consultation with minimal waiting time.
5. Travel & Logistics — Assistance with visa invitation letters, accommodation near Ruijin Hospital, and Shanghai airport transfers.
6. On-Site Concierge — Bilingual coordinators accompany you throughout your hospital visits, managing registration, translation, and communication.
7. Diagnostic Support — Full coordination of pulmonary function testing, bronchoscopy, HRCT, and microbiological investigations.
8. Post-Treatment Follow-Up — Test result translation, treatment plan interpretation, and remote follow-up coordination after you return home.

Book a Consultation

If you are seeking expert pulmonology care in Shanghai — whether for a complex lung infection, interstitial lung disease, severe asthma, COPD, pulmonary hypertension, or a second opinion on a challenging respiratory diagnosis — CMCS can arrange a specialist consultation with Ruijin Hospital's pulmonology team.

📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com